BioSpace News Archive

SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today presented additional details from studies of SBT101.

StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2022, and provided an update on its business progress.

Genascence Corporation (“Genascence”), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced that additional safety data from the Phase 1 clinical trial of GNSC-001.

Capsida Biotherapeutics (“Capsida”), the only fully integrated gene therapy platform company that through intravenous (IV) delivery of a single, engineered capsid can target single or multiple organs simultaneously while limiting exposure to non-targeted organs, today announced an oral presentation and a poster presentation delivered at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Teva Announces New Findings Highlighting Potential of ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges.

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration (‘FDA’) to discuss the development IHL-42X.

Jounce Therapeutics, Inc. announced that Jounce management will participate at the following upcoming investor conferences:

Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual meeting in Washington DC. May 15-19, 2022.

scPharmaceuticals Inc. announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24 at 3:00pm EDT, at the Fontainebleau Miami Beach Hotel in Miami, FL.